St Jude Medical Inc: (NYSE: STJ)

$45.87

0.21 (0.46%)

Volume 1,171,160

Jun 18 04:03 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		45.45 - 45.92
	
		52wk Low - High
		30.25 - 47.45
	
		Previous Close
		45.66
	
		Avg. Volume
		1,881,800
	
		Industry
		MED PRODUCTS
	
		Market Cap
		13.00 B
	
		Div - Yield
		1.00 - 2.18
	
		Beta
		0.85
	
		P/E (F1)
		12.41
	
		Current Year Est.
		3.69
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		184 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/9/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            12.41
                        
                            PEG Ratio
                            1.45
                        
                            Current Year Est.
                            3.69
                        
                            Current Quarter Estimate
                            0.94
                        
                            Most Accurate Estimate
                            0.94
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-17-2013
                        
                            EPS Last Year
                            3.55
                        
                            Expected Earnings Growth
                            8.58%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
St. Jude Medical, Inc. is dedicated to making life better for cardiac, neurological and chronic pain patients worldwide through excellence in medical device technology and services. The Company has five major focus areas that include cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation.   
Full STJ Company Report

 Analyst Report on STJ

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
STJ Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.94	0.88	3.69	3.93
Number of Estimates	18	18	19	19
Low Estimate	0.92	0.84	3.60	3.75
High Estimate	0.95	0.90	3.73	NA
Year Ago EPS	0.88	0.83	3.48	3.69
EPS Growth	6.63%	5.89%	6.17%	6.42%

More STJ Estimates

Average Earnings Estimates for STJ

EPS Growth for STJ

Industry Analysis

Name	Symbol	Previous Close
ST JUDE MEDICAL	STJ	45.87
HAEMONETICS CP	HAE	42.71
ATRICURE INC	ATRC	9.12
BAXANO SURGICAL	BAXS	2.28
CARDICA INC	CRDC	1.19
ESSILOR INTL SA	ESLOY	55.99
INVIVO THERAPT	NVIV	3.89
PURE BIOSCIENCE	PURE	0.41
SHANDONG WEIGAO	SHWGF	1.29
ABAXIS INC	ABAX	46.89

Sector:Medical>> Industry:MED PRODUCTS

COMPARE TICKER vs. Its Peers

Zacks Commentary

BSX Commences U.S. INTREPID Trial

Jun 18, 2013

FDA Nod for STJ's Ellipse & Assura

Jun 13, 2013

St. Jude Expands Neuro Offerings

Jun 10, 2013

GB Aims at Growth, Realigns Biz

Jun 07, 2013

STJ Begins U.S. Trial for EnligHTN

Jun 05, 2013

Medtronic Endovascular Biz in Focus

May 31, 2013

St. Jude Begins EnligHTNment Study

May 24, 2013

Medtronic Beats Earnings, Results Stronger

May 22, 2013

More STJ Zacks Commentary

Financials

EPS TTM	3.55
Sales	5,503
Net Income	763
Price/Earnings	12.92
Price/Book	3.39
Price/Cash Flow	10.33
Price/Sales	2.39

More STJ Financials

News

Research and Markets Adds Report: St. Jude Medical, Inc. 2013 Market Share Analysis - Close-Up Media

Jun 18, 2013

Next Resistance Level for St Jude Medical (STJ) is $45.71 - Financial News Network Online - Pivot Alerts

Jun 17, 2013

Research and Markets: St. Jude Medical, Inc. 2013 Market Share Analysis Gives Comprehensive Coverage of the Latest Financial Deals Involving the Company and its Subsidiaries - Businesswire

Jun 17, 2013

St. Jude Medical, Inc. 2013 Market Share Analysis Gives Comprehensive Coverage of the Latest Financial Deals Involving the Company and its Subsidiaries - M2

Jun 17, 2013

Beat the Market With the Father`s Day Portfolio - TheMotleyFool

Jun 16, 2013

FDA Nod for STJ's Ellipse & Assura - Zacks.Com

Jun 14, 2013

St Jude Medical (STJ) Showing Bullish Technicals With Resistance At $46.01 - Freshbrewedmedia

Jun 14, 2013

St. Jude Medical Gets FDA Approval of High-Voltage Defibrillators with New Safety Features - Close-Up Media

Jun 14, 2013

See All News Stories on STJ

Broker Recommendations

Current ABR	2.12
ABR (Last Week)	2.12
# of recs in ABR	25
Average Target Price	46.06
Industry Rank by ABR	184 out of 265
Rank in Industry	9 out of 73

More STJ Broker Recommendations

Day Low - High	45.45 - 45.92
52wk Low - High	30.25 - 47.45
Previous Close	45.66
Avg. Volume	1,881,800
Industry	MED PRODUCTS
Market Cap	13.00 B
Div - Yield	1.00 - 2.18
Beta	0.85
P/E (F1)	12.41
Current Year Est.	3.69
Quarterly Earnings ESP	0.00%

P/E (F1)	12.41
PEG Ratio	1.45
Current Year Est.	3.69
Current Quarter Estimate	0.94
Most Accurate Estimate	0.94
Earnings ESP	0.00%
Next Earnings Report Date	07-17-2013
EPS Last Year	3.55
Expected Earnings Growth	8.58%

Username: Password:

Remember me [?]

St Jude Medical Inc: (NYSE: STJ)

$45.87

0.21 (0.46%)

Volume 1,171,160

Jun 18 04:03 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED PRODUCTS

Zacks Commentary

Financials

News

Broker Recommendations